Human Wharton's jelly mesenchymal stem cells protect axotomized rat retinal ganglion cells via secretion of anti-inflammatory and neurotrophic factors.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

Mesenchymal Stem Cell Transplantation/*methods ; Retinal Degeneration/*therapy ; Retinal Ganglion Cells/*pathology ; Wharton Jelly/*cytology; Animals ; Anti-Inflammatory Agents/metabolism ; Axotomy/adverse effects ; Disease Models, Animal ; Female ; Humans ; Intravitreal Injections ; Mesenchymal Stem Cells/metabolism ; Nerve Growth Factors/metabolism ; Rats ; Rats, Sprague-Dawley ; Retinal Degeneration/etiology ; Retinal Degeneration/pathology ; Treatment Outcome ; Umbilical Cord/cytology

Mesenchymal stem cell (MSC) transplantation is emerging as an ideal tool to restore the wounded central nervous system (CNS). MSCs isolated from extra-embryonic tissues have some advantages compared to MSCs derived from adult ones, such as an improved proliferative capacity, life span, differentiation potential and immunomodulatory properties. In addition, they are more immunoprivileged, reducing the probability of being rejected by the recipient. Umbilical cords (UCs) are a good source of MSCs because they are abundant, safe, non-invasively harvested after birth and, importantly, they are not encumbered with ethical problems. Here we show that the intravitreal transplant of Wharton´s jelly mesenchymal stem cells isolated from three different human UCs (hWJMSCs) delays axotomy-induced retinal ganglion cell (RGC) loss. In vivo, hWJMSCs secrete anti-inflammatory molecules and trophic factors, the latter alone may account for the elicited neuroprotection. Interestingly, this expression profile differs between naive and injured retinas, suggesting that the environment in which the hWJMSCs are modulates their secretome. Finally, even though the transplant itself is not toxic for RGCs, it is not innocuous as it triggers a transient but massive infiltration of Iba1 ⁺ cells from the choroid to the retina that alters the retinal structure.

Graefes Arch Clin Exp Ophthalmol. 2011 Jul;249(7):1021-8. (PMID: 21360302)
Stem Cells. 2006 May;24(5):1294-301. (PMID: 16410387)
Exp Eye Res. 2009 Jun 15;89(1):32-41. (PMID: 19268467)
J Neurobiol. 1993 Jan;24(1):23-36. (PMID: 8419522)
J Neurosci. 2017 Jun 21;37(25):6113-6124. (PMID: 28539419)
Brain Behav Immun. 2016 May;54:45-58. (PMID: 26732826)
Front Neurosci. 2017 Apr 26;11:235. (PMID: 28491019)
J Neuroinflammation. 2016 Apr 28;13(1):93. (PMID: 27126275)
Exp Hematol. 2003 Oct;31(10):890-6. (PMID: 14550804)
Exp Hematol. 2014 Sep;42(9):793-803.e1. (PMID: 24746876)
J Neurosci. 2006 Nov 29;26(48):12439-46. (PMID: 17135405)
Invest Ophthalmol Vis Sci. 2009 Jan;50(1):424-31. (PMID: 18775855)
Acta Biochim Biophys Sin (Shanghai). 2014 Dec;46(12):1056-65. (PMID: 25377438)
J Endod. 2018 Jan;44(1):126-132. (PMID: 29079052)
Sci Rep. 2017 Mar 24;7(1):408. (PMID: 28341839)
Exp Eye Res. 2018 May;170:40-50. (PMID: 29452106)
Invest Ophthalmol Vis Sci. 2016 Jan 1;57(1):81-93. (PMID: 26780312)
Stem Cells. 2012 Sep;30(9):2044-53. (PMID: 22821677)
ACS Chem Neurosci. 2016 Apr 20;7(4):454-63. (PMID: 26979823)
Stem Cells Dev. 2009 Apr;18(3):399-409. (PMID: 18665766)
Invest Ophthalmol Vis Sci. 2015 Sep;56(10):6095-112. (PMID: 26393669)
PLoS One. 2015 Jun 24;10(6):e0128973. (PMID: 26107378)
Stem Cells. 2015 Oct;33(10):3006-16. (PMID: 26175331)
Methods Cell Biol. 2008;86:101-19. (PMID: 18442646)
PLoS One. 2009 Sep 25;4(9):e7178. (PMID: 19779605)
Cell Transplant. 2011;20(3):391-406. (PMID: 20719093)
PLoS One. 2015 Jun 10;10(6):e0127992. (PMID: 26061052)
PLoS One. 2013 Aug 05;8(8):e69938. (PMID: 23940534)
Recent Pat Inflamm Allergy Drug Discov. 2018;12(1):59-68. (PMID: 29485014)
PLoS One. 2014 Apr 15;9(4):e93726. (PMID: 24736473)
J Neurosci. 1989 Apr;9(4):1263-72. (PMID: 2467970)
Cytotherapy. 2005;7(5):393-5. (PMID: 16236628)
Cytotherapy. 2016 Apr;18(4):497-509. (PMID: 26971678)
Stem Cell Res Ther. 2017 Dec 22;8(1):288. (PMID: 29273086)
Exp Neurol. 2009 Apr;216(2):439-48. (PMID: 19320003)
Cytokine Growth Factor Rev. 2009 Oct-Dec;20(5-6):419-27. (PMID: 19926330)
Brain Res. 1993 Feb 5;602(2):304-17. (PMID: 8448673)
Cell Tissue Res. 2018 Apr;372(1):51-65. (PMID: 29204746)
Invest Ophthalmol Vis Sci. 2016 Nov 1;57(14):6098-6106. (PMID: 27832276)
Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):2307-12. (PMID: 20080612)
Cell Physiol Biochem. 2009;24(3-4):307-16. (PMID: 19710545)
Stem Cells Dev. 2015 Nov 15;24(22):2649-59. (PMID: 26414086)
Cytotherapy. 2006;8(4):315-7. (PMID: 16923606)
PLoS One. 2008 Apr 02;3(4):e1886. (PMID: 18382669)
Invest Ophthalmol Vis Sci. 1996 Mar;37(4):489-500. (PMID: 8595949)
Invest Ophthalmol Vis Sci. 2013 Feb 01;54(2):974-85. (PMID: 23307961)
Mol Immunol. 2017 Jul;87:293-299. (PMID: 28531813)
Exp Eye Res. 2011 Apr;92(4):260-7. (PMID: 21315070)
Cell Transplant. 2015;24(5):819-28. (PMID: 24593908)
Stem Cells Transl Med. 2017 Apr;6(4):1273-1285. (PMID: 28198592)
Trends Pharmacol Sci. 2013 Jul;34(7):413-23. (PMID: 23796953)
Curr Eye Res. 2018 Jun;43(6):810-820. (PMID: 29505314)
J Neuroinflammation. 2017 Nov 09;14(1):218. (PMID: 29121969)
Exp Hematol. 2016 Feb;44(2):138-150.e1. (PMID: 26577566)
PLoS One. 2014 Oct 27;9(10):e110722. (PMID: 25347773)
Stem Cells Transl Med. 2016 Nov;5(11):1441-1446. (PMID: 27412883)
J Neuroophthalmol. 2011 Dec;31(4):331-8. (PMID: 21799446)
Blood. 2003 May 1;101(9):3722-9. (PMID: 12506037)
Invest Ophthalmol Vis Sci. 2016 Jul 1;57(8):3533-44. (PMID: 27379578)
Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3978-83. (PMID: 9520478)
Stem Cells Int. 2016;2016:5078619. (PMID: 26649049)
Invest Ophthalmol Vis Sci. 2009 Aug;50(8):3860-8. (PMID: 19264888)
Blood. 2008 Jan 1;111(1):430-8. (PMID: 17909081)
Mediators Inflamm. 2017;2017:7034143. (PMID: 29081602)
Stem Cells. 2011 Oct;29(10):1549-58. (PMID: 21898680)
Stem Cells Dev. 2011 Mar;20(3):547-57. (PMID: 20923277)
Cell Transplant. 2011;20(5):655-67. (PMID: 21054940)
PLoS One. 2014 Oct 07;9(10):e109305. (PMID: 25290916)
Liver Transpl. 2009 May;15(5):484-95. (PMID: 19399744)
Brain. 2014 Feb;137(Pt 2):503-19. (PMID: 24176979)
PLoS One. 2010 Feb 02;5(2):e9016. (PMID: 20126406)
Stroke. 2011 Jul;42(7):2045-53. (PMID: 21566227)
Best Pract Res Clin Haematol. 2011 Mar;24(1):59-64. (PMID: 21396593)
Blood. 2002 May 15;99(10):3838-43. (PMID: 11986244)
Sci Rep. 2015 Nov 09;5:16167. (PMID: 26548646)
Front Neuroanat. 2017 Mar 06;11:14. (PMID: 28321183)
Neurochem Res. 2010 May;35(5):820-9. (PMID: 20180018)

0 (Anti-Inflammatory Agents)
0 (Nerve Growth Factors)

Date Created: 20181104 Date Completed: 20191125 Latest Revision: 20191125

20250114

PMC6214908

10.1038/s41598-018-34527-z

30389962